On April 7, 2020, Choi, Hwan Geun; Ko, Eun Hwa; Kim, So Yeong; Kang, Seok Yong; Ryu, Hui Yun; Kim, Su Heon published a patent.Recommanded Product: 16230-24-3 The title of the patent was Preparation of pyrido[2,3-d]pyrimidine derivatives, and pharmaceutical compositions comprising them as active ingredients for preventing or treating cancer. And the patent contained the following:
The present invention relates to pyrido[2,3-d]pyrimidine derivatives I [double-dotted line = single bond or double bond; R1 = H, linear or branched alkyl, aryl, etc.; R2 = H, or linear or branched alkoxy; R3 = H or -NH-C(=O)-CH=CH2; n = 0 or 1; A1 = -C(R4)=, -N= or -N(R5)-; R4 = H, halogen or (un)substituted heterocycloalkyl; R5 = H, or linear or branched alkoxyalkyl; A2 = -C(R6)= or -N=; R6 = -NRaRb or -(C=O)NRcRd; Ra, Rb, Rc and Rd = independently H, (un)substituted linear or branched alkyl, etc.], a method for preparing them, and pharmaceutical compositions comprising them as active ingredients for preventing or treating cancer. For example, compound II (preparation given) was subjected to reaction with N1,N1,N2-trimethylethane-1,2-diamine followed by reduction of the nitro group and coupling with acryloyl chloride to provide compound III. The invention compounds exhibit inhibitory activity against various kinases, and in particular, exhibit high inhibitory ability against EGFR (epidermal growth factor receptor) wild type or mutants, and thus they can be usefully used in the treatment of diseases associated with the activity of various kinases, particularly cancers expressing EGFR wild type or EGFR mutation. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Recommanded Product: 16230-24-3
The Article related to pyridopyrimidine derivative preparation kinase egfr inhibitor cancer treatment, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics